Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 10;2010(11):CD007802.
doi: 10.1002/14651858.CD007802.pub2.

Milrinone for persistent pulmonary hypertension of the newborn

Dirk Bassler  1 , Karen Kreutzer, Patrick McNamara, Haresh Kirpalani
Affiliations

Milrinone for persistent pulmonary hypertension of the newborn

Dirk Bassler et al. Cochrane Database Syst Rev. .

Abstract

Background: Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation with inhaled nitric oxide (iNO). However, iNO is not available in all countries and not all infants will respond to iNO. Milrinone is a phosphodiesterase III inhibitor which induces pulmonary vasodilatation by its actions through a cyclic adenylate monophosphate mediated signaling pathway.

Objectives: To assess efficacy and safety in infants with PPHN either treated with: milrinone compared with placebo or no treatment; milrinone compared with iNO; milrinone as an adjunct to iNO compared with iNO alone; milrinone compared with potential treatments for PPHN other than iNO.

Search strategy: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 2, 2010), MEDLINE and EMBASE databases from their inception until January 2010. We searched the reference lists of potentially relevant studies without any language restriction.

Selection criteria: Fully published randomized controlled trials (RCTs) and quasi-RCTs comparing milrinone with placebo, iNO or potential treatments other than iNO in neonates with PPHN were included if trials reported any clinical outcome.

Data collection and analysis: We found no studies meeting the criteria for inclusion in this review.

Main results: We found no studies meeting the criteria for inclusion in this review.

Authors' conclusions: The efficacy and safety of milrinone in the treatment of PPHN are not known and its use should be restricted within the context of RCTs. Such studies should address a comparison of milrinone with placebo (in clinical situations where iNO is not available) or, in well resourced countries, should compare milrinone with iNO or as an adjunct to iNO compared with iNO alone.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

  • doi: 10.1002/14651858.CD007802

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

    1. Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biology of the Neonate 2006;89(1):1‐5. - PubMed
    1. McNamara PJ, Laique F, Muang‐In S, Whyte HE. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. Journal of Critical Care 2006;21(2):217‐22. - PubMed

References to ongoing studies

    1. Kirpalani H. Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn. ClinicalTrials.gov.

Additional references

    1. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD000509.pub3] - DOI - PubMed
    1. Barton P, Garcia J, Kouatli A, Kitchen L, Zorka A, Lindsay C, et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double‐blinded, randomized, placebo‐controlled, interventional study. Chest 1996;109(5):1302‐12. - PubMed
    1. Clarke WR, Uezono S, Chambers A, Doepfner P. The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulmonary Pharmacology 1994;7(2):81‐9. - PubMed
    1. Farrow KN, Fliman P, Steinhorn RH. The disease treated with ECMO: focus on PPHN. Seminars in Perinatology 2005;29(1):8‐14. - PubMed
    1. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD000399.pub2] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources